The efficacy of the Dengue vaccine has been successfully demonstrated for the first time in Bangladesh, a country severely affected by the dengue epidemic.

 A recent study conducted by scientists from the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B) and the Larner College of Medicine at the University of Vermont has successfully tested a single-dose dengue vaccine, TV005, in Bangladesh. This breakthrough raises hopes for the country to combat the epidemic. The study, published in The Lancet Infectious Diseases journal, revealed that the vaccine demonstrated safety and immune responsiveness in both children and adults, effectively targeting all four dengue serotypes. 

Dengue fever, a mosquito-borne virus, is rapidly spreading worldwide, particularly in tropical regions. While mild cases result in fever and bone pain, severe cases can lead to shock, bleeding, and even death. Public health experts have urged the authorities in Bangladesh to enhance healthcare facilities as the country grapples with a significant increase in cases, which are up to five times higher than those reported by the government. 

Furthermore, other countries in South Asia are also witnessing a surge in dengue outbreaks. This year, Bangladesh has experienced its worst outbreak on record, overwhelming hospitals in the capital city of Dhaka, as stated by the ICDDR, B. The statement emphasized the urgent need for the development of a tetravalent vaccine that targets all four serotypes, as the current treatment options are limited to fluid management and symptom control. 

As of Thursday, Bangladesh has reported a total of 967 deaths and nearly 200,000 hospitalizations due to dengue this year, marking the highest figures in the past 23 years.